<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2019-21-103-109</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-5481</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НЕВРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NEUROLOGY</subject></subj-group></article-categories><title-group><article-title>Влияние сертралина на когнитивные, психомоторные и личностно-поведенческие показатели при терапии депрессии (клинический случай)</article-title><trans-title-group xml:lang="en"><trans-title>The effect of sertraline on cognitive, psychomotor and personality-behavioural parameters in therapy of depression (clinical case)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6018-402X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вазагаева</surname><given-names>Т. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Vazagayeva</surname><given-names>T. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вазагаева Тамара Иродионовна, к.м.н., старший научный сотрудник отделения новых средств и методов терапии Отдела пограничной психиатрии</p><p>119034, Россия, Москва, Кропоткинский пер., д. 23</p></bio><bio xml:lang="en"><p>Tamara I. Vazagayeva, Cand. of Sci. (Med), Senior Researcher of the Department of New Means and Methods of Therapy of the Department of Boundary Psychiatry</p><p>23, Kropotkinsky lane, Moscow, 119034, Russia</p></bio><email xlink:type="simple">vazagaeva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7045-0547</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ахапкин</surname><given-names>Р. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Akhapki</surname><given-names>R. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ахапкин Роман Витальевич, к.м.н., руководитель отделения новых средств и методов терапии Отдела пограничной психиатрии</p><p>119034, Россия, Москва, Кропоткинский пер., д. 23</p></bio><bio xml:lang="en"><p>Roman V. Akhapkin, Cand. of Sci. (Med), Head of the Department of New Means and Methods of Therapy at the Department of Boundary Psychiatry</p><p>23, Kropotkinsky lane, Moscow, 119034, Russia</p></bio><email xlink:type="simple">4ahapkin@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2676-2014</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Корендюхина</surname><given-names>А. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Korendyukhina</surname><given-names>A. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Корендюхина Анна Олеговна, аспирант отделения новых средств и методов терапии Отдела пограничной психиатрии</p><p>119034, Россия, Москва, Кропоткинский пер., д. 23</p></bio><bio xml:lang="en"><p>Anna O. Korendyukhina, Postgraduate Student of the Department of New Means and Methods of Therapy of the Department of Boundary Psychiatry</p><p>23, Kropotkinsky lane, Moscow, 119034, Russia</p></bio><email xlink:type="simple">annikore@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3001-6524</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Файзуллоев</surname><given-names>А. З.</given-names></name><name name-style="western" xml:lang="en"><surname>Fayzulloyev</surname><given-names>A. Z.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Файзуллоев Асириддин Зубайдуллоевич, к.м.н., старший научный сотрудник отделения новых средств и методов терапии Отдела пограничной психиатрии</p><p>119034, Россия, Москва, Кропоткинский пер., д. 23</p></bio><bio xml:lang="en"><p>Asiriddin Z. Fayzulloyev, Cand. of Sci. (Med), Senior Researcher of the Department of New Means and Methods of Therapy of the Department of Boundary Psychiatry</p><p>23, Kropotkinsky lane, Moscow, 119034, Russia</p></bio><email xlink:type="simple">a.fajzuloev@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Национальный медицинский исследовательский центр психиатрии и наркологии им. В.П. Сербского<country>Россия</country></aff><aff xml:lang="en">V.P. Serbsky Federal Medical Research Center of Psychiatry and Narcology<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>26</day><month>01</month><year>2020</year></pub-date><volume>0</volume><issue>21</issue><fpage>103</fpage><lpage>109</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Вазагаева Т.И., Ахапкин Р.В., Корендюхина А.О., Файзуллоев А.З., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Вазагаева Т.И., Ахапкин Р.В., Корендюхина А.О., Файзуллоев А.З.</copyright-holder><copyright-holder xml:lang="en">Vazagayeva T.I., Akhapki R.V., Korendyukhina A.O., Fayzulloyev A.Z.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/5481">https://www.med-sovet.pro/jour/article/view/5481</self-uri><abstract><p>В статье рассмотрен клинический случай применения антидепрессанта сертралина в дозе 100 мг у пациентки с первично возникшим депрессивным эпизодом умеренной степени тяжести. К моменту обращения состояние длилось 16 месяцев, наблюдалась симптоматика тревожно-апатической депрессии эндореактивного типа. В процессе терапии отмечалась позитивная терапевтическая динамика с достижением клинической ремиссии к концу 6-й недели лечения. Редукция тревожно- депрессивной симптоматики сопровождалась положительной динамикой психомоторных показателей с нормализацией баланса процессов возбуждения и торможения, когнитивных показателей с улучшением исполнительных функций в виде повышения полинезависимости, функциональной подвижности нервных процессов и стрессоустойчивости, повышением продуктивности и устойчивости внимания, оперативной памяти. Существенные позитивные изменения наблюдались при анализе формально-динамических личностных характеристик: снизился уровень психомоторной и интеллектуальной эмоциональности, что отражает уменьшение интенсивности эмоционального переживания по поводу расхождения между ожидаемым и реальным результатом деятельности, повысились уровни интеллектуальной пластичности, отражающей гиб- кость мышления, интеллектуальной и коммуникативной скорости, т.е. скорости умственных процессов, речевой активности и вербализации. В личностно-эмоциональной сфере отмечалось повышение фрустрационной толерантности, сбалансированности экстрапунитивной, интрапунитивной и импунитивной направленностей реакций, увеличение частоты типа реакции «с фиксацией на препятствии» и уменьшение частоты типа реакций «с фиксацией на самозащите», снижение индекса агрессивности. Вместе с тем не наблюдалось изменений в методике «типы поведенческой активности»: сохранялся выраженный поведенческий паттерн типа «А» так называемого «стресс-коронарного» поведения. Выявленные изменения указывают на повышение адаптивных возможностей личности на фоне купирующей антидепрессивной фармакотерапии сертралином.</p></abstract><trans-abstract xml:lang="en"><p>The article presents a clinical case of the use of the antidepressant sertraline at a dose of 100 mg in a patient with a primary moderate depressive episode. At the time of treatment, the condition lasted 16 months, and symptomatology of anxiousapathic depression of endoreactive type was observed. Positive therapeutic dynamics were observed in the course of therapy with achieving clinical remission by the end of the 6th week of treatment. The reduction of anxiodepressive symptomatology was accompanied by positive dynamics of psychomotor indices with normalization of balance of excitation and inhibition processes, cognitive indices with improvement of executive functions in the form of increase of polyindependence, functional mobility of nervous processes and stress resistance, increase of productivity and stability of attention, operative memory. Significant positive changes were observed in the analysis of formal-dynamic personal characteristics: the level of psychomotor and intellectual emotionality decreased, which reflects a decrease in the intensity of emotional experience of the divergence between the expected and real results of activity, the levels of intellectual plasticity reflecting the flexibility of thinking, intellectual and communicative speed, i.e. the speed of mental processes, speech activity and verbalization increased. In the personal- emotional sphere there was an increase in frustration tolerance, balance of extrapunitive, intrapunitive and impulsive directions of reactions, increase in frequency of «obstacle-fixed» type of reaction and decrease in frequency of «self-protection» type of reaction, decrease in aggressiveness index. At the same time there were no changes in «behavioural activity types» technique: the expressed behavioural pattern of «A» type of so-called «stress-coronary» behaviour was preserved. The revealed changes indicate an increase in the adaptive capacity of the individual against the background of remitative antidepressive pharmacotherapy with sertraline.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>сертралин</kwd><kwd>антидепрессанты</kwd><kwd>депрессивные расстройства</kwd><kwd>когнитивные функции</kwd><kwd>психомоторные функции</kwd><kwd>личностные особенности</kwd></kwd-group><kwd-group xml:lang="en"><kwd>sertraline</kwd><kwd>antidepressants</kwd><kwd>depressive disorders</kwd><kwd>cognitive functions</kwd><kwd>psychomotor functions</kwd><kwd>personality traits</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">McRae A.L., Brady K.T. Review of sertraline and its clinical applications in psychiatric disorders. Expert Opin Pharmacother. 2001;2(5):883-892. doi: 10.1517/14656566.2.5.883.</mixed-citation><mixed-citation xml:lang="en">McRae A.L., Brady K.T. Review of sertraline and its clinical applications in psychiatric disorders. Expert Opin Pharmacother. 2001;2(5):883-892. doi: 10.1517/14656566.2.5.883.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Sheehan D.V., Kamijima K. An evidence-based review of the clinical use of sertraline in mood and anxiety disorders. Int Clin Psychopharmacol. 2009;24(2):43-60. doi: 10.1097/YIC.0b013e3282f4b616.</mixed-citation><mixed-citation xml:lang="en">Sheehan D.V., Kamijima K. An evidence-based review of the clinical use of sertraline in mood and anxiety disorders. Int Clin Psychopharmacol. 2009;24(2):43-60. doi: 10.1097/YIC.0b013e3282f4b616.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Tatsumi M., Groshan K., Blakely R.D., Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340(2-3):249-58. doi: 10.1016/s0014-2999(97)01393-9.</mixed-citation><mixed-citation xml:lang="en">Tatsumi M., Groshan K., Blakely R.D., Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340(2-3):249-58. doi: 10.1016/s0014-2999(97)01393-9.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kitaichi Y., Inoue T., Nakagawa S., Boku S., Kakuta A., Izumi T., Koyama T. Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. Eur J Pharmacol. 2010;647(1-3):90-6. doi: 10.1016/j.ejphar.2010.08.026.</mixed-citation><mixed-citation xml:lang="en">Kitaichi Y., Inoue T., Nakagawa S., Boku S., Kakuta A., Izumi T., Koyama T. Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. Eur J Pharmacol. 2010;647(1-3):90-6. doi: 10.1016/j.ejphar.2010.08.026.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Schrijvers D., Maas Y.J., Pier M.P., Madani Y., Hulstijn W., Sabbe B.G. Psychomotor changes in major depressive disorder during sertraline treatment. Neuropsychobiology. 2009;59(1):34-42. doi: 10.1159/000205516.</mixed-citation><mixed-citation xml:lang="en">Schrijvers D., Maas Y.J., Pier M.P., Madani Y., Hulstijn W., Sabbe B.G. Psychomotor changes in major depressive disorder during sertraline treatment. Neuropsychobiology. 2009;59(1):34-42. doi: 10.1159/000205516.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Taler M., Miron O., Gil-Ad I., Weizman A. Neuroprotective and procognitive effects of sertraline: in vitro and in vivo studies. Neurosci Lett. 2013;550:93-7. doi: 10.1016/j.neulet.2013.06.033.</mixed-citation><mixed-citation xml:lang="en">Taler M., Miron O., Gil-Ad I., Weizman A. Neuroprotective and procognitive effects of sertraline: in vitro and in vivo studies. Neurosci Lett. 2013;550:93-7. doi: 10.1016/j.neulet.2013.06.033.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Alpert M., Pouget E.R., Silva R.R. Reflections of depression in acoustic measures of the patient’s speech. J Affect Disord. 2001;66(1):59-69. doi: 10.1016/s0165-0327(00)00335-9.</mixed-citation><mixed-citation xml:lang="en">Alpert M., Pouget E.R., Silva R.R. Reflections of depression in acoustic measures of the patient’s speech. J Affect Disord. 2001;66(1):59-69. doi: 10.1016/s0165-0327(00)00335-9.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ravindran A.V., Teehan M.D., Bakish D., Yatham L., Oreilly R., Fernando M.L., Manchanda R., Charbonneau Y., Buttars J.: The impact of sertraline, desipramine, and placebo on psychomotor functioning in depression. Hum. Psychopharmacol. 1995;10:273–281. doi: 10.1002/hup.470100404.</mixed-citation><mixed-citation xml:lang="en">Ravindran A.V., Teehan M.D., Bakish D., Yatham L., Oreilly R., Fernando M.L., Manchanda R., Charbonneau Y., Buttars J.: The impact of sertraline, desipramine, and placebo on psychomotor functioning in depression. Hum. Psychopharmacol. 1995;10:273–281. doi: 10.1002/hup.470100404.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Constant E.L., Adam S., Gillain B., Seron X., Bruyer R., Seghers A. Effects of sertraline on depressive symptoms and attentional and executive functions in major depression. Depress Anxiety. 2005;21(2):78-89. doi: 10.1002/da.20060.</mixed-citation><mixed-citation xml:lang="en">Constant E.L., Adam S., Gillain B., Seron X., Bruyer R., Seghers A. Effects of sertraline on depressive symptoms and attentional and executive functions in major depression. Depress Anxiety. 2005;21(2):78-89. doi: 10.1002/da.20060.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ахапкин Р.В., Федорова А.И., Файзуллоев А.З., Емелин К.Э. Влияние сертралина на когнитивные функции у пациентов с униполярными депрессивными расстройствами. Медицинский Совет. 2018;(18):24-29. doi: 10.21518/2079-701X-2018-18-24-29. Akhapkin R.V., Fedorova A.I., Faizulloev A.Z., Emelin K.E. Effects of sertraline on cognitive function in patients with unipolar depressive disorders. Meditsinskiy sovet = Medical Council. 2018;(18):24-29. (In Russ.) doi: 10.21518/2079-701X-2018-18-24-29.</mixed-citation><mixed-citation xml:lang="en">Ахапкин Р.В., Федорова А.И., Файзуллоев А.З., Емелин К.Э. Влияние сертралина на когнитивные функции у пациентов с униполярными депрессивными расстройствами. Медицинский Совет. 2018;(18):24-29. doi: 10.21518/2079-701X-2018-18-24-29. Akhapkin R.V., Fedorova A.I., Faizulloev A.Z., Emelin K.E. Effects of sertraline on cognitive function in patients with unipolar depressive disorders. Meditsinskiy sovet = Medical Council. 2018;(18):24-29. (In Russ.) doi: 10.21518/2079-701X-2018-18-24-29.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Culang-Reinlieb M.E., Sneed J.R., Keilp J.G., Roose S.P. Change in cognitive functioning in depressed older adults following treatment with sertraline or nortriptyline. Int J Geriatr Psychiatry. 2012;27(8):777–784. doi: 10.1002/gps.2783.</mixed-citation><mixed-citation xml:lang="en">Culang-Reinlieb M.E., Sneed J.R., Keilp J.G., Roose S.P. Change in cognitive functioning in depressed older adults following treatment with sertraline or nortriptyline. Int J Geriatr Psychiatry. 2012;27(8):777–784. doi: 10.1002/gps.2783.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ekselius L., Von Knorring L. Changes in personality traits during treatment with sertraline or citalopram. Br J Psychiatry. 1999;174:444–448. doi: 10.1192/bjp.174.5.444.</mixed-citation><mixed-citation xml:lang="en">Ekselius L., Von Knorring L. Changes in personality traits during treatment with sertraline or citalopram. Br J Psychiatry. 1999;174:444–448. doi: 10.1192/bjp.174.5.444.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Tang T.Z., DeRubeis R.J., Hollon S.D., Amsterdam J., Shelton R., Schalet B. Personality change during depression treatment: a placebo-controlled trial. Arch Gen Psychiatry. 2009;66(12):1322–1330. doi: 10.1001/archgenpsychiatry.2009.166.</mixed-citation><mixed-citation xml:lang="en">Tang T.Z., DeRubeis R.J., Hollon S.D., Amsterdam J., Shelton R., Schalet B. Personality change during depression treatment: a placebo-controlled trial. Arch Gen Psychiatry. 2009;66(12):1322–1330. doi: 10.1001/archgenpsychiatry.2009.166.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Harmer C.J., Bhagwagar Z., Perrett D.I., Völlm B.A., Cowen P.J., Goodwin G.M. Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology. 2003;28:148–52. doi: 10.1038/sj.npp.1300004.</mixed-citation><mixed-citation xml:lang="en">Harmer C.J., Bhagwagar Z., Perrett D.I., Völlm B.A., Cowen P.J., Goodwin G.M. Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology. 2003;28:148–52. doi: 10.1038/sj.npp.1300004.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Knutson B., Wolkowitz O.M., Cole S.W., Chan T., Moore E.A., Johnson R.C., et al. Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry. 1998;155:373–379. doi: 10.1176/ajp.155.3.373.</mixed-citation><mixed-citation xml:lang="en">Knutson B., Wolkowitz O.M., Cole S.W., Chan T., Moore E.A., Johnson R.C., et al. Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry. 1998;155:373–379. doi: 10.1176/ajp.155.3.373.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Simmons A.N., Arce E., Lovero K.L., Stein M.B., Paulus M.P. Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers. Int J Neuropsychopharmacol. 2009;12(8):1009–1020. doi: 10.1017/S1461145709990149.</mixed-citation><mixed-citation xml:lang="en">Simmons A.N., Arce E., Lovero K.L., Stein M.B., Paulus M.P. Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers. Int J Neuropsychopharmacol. 2009;12(8):1009–1020. doi: 10.1017/S1461145709990149.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Tse W.S., Bond A.J. Serotonergic involvement in the psychosocial dimension of personality. J Psychopharmacol. 2001;15:195–198. doi: 10.1177/026988110101500313.</mixed-citation><mixed-citation xml:lang="en">Tse W.S., Bond A.J. Serotonergic involvement in the psychosocial dimension of personality. J Psychopharmacol. 2001;15:195–198. doi: 10.1177/026988110101500313.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Fava M., Rosenbaum J.F. Anger attacks in patients with depression. J Clin Psychiatry. 1999;60(15):21–4. doi: 10.1002/(sici)1520-6394(1998)8:1+&lt;59::aid-da9&gt;3.3.co;2-p.</mixed-citation><mixed-citation xml:lang="en">Fava M., Rosenbaum J.F. Anger attacks in patients with depression. J Clin Psychiatry. 1999;60(15):21–4. doi: 10.1002/(sici)1520-6394(1998)8:1+&lt;59::aid-da9&gt;3.3.co;2-p.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Dunlop B.W., DeFife J.A., Marx L., Garlow S.J., Nemeroff C.B., Lilienfeld S.O. The effects of sertraline on psychopathic traits. Int Clin Psychopharmacol. 2011;26(6):329–337. doi: 10.1097/YIC.0b013e32834b80df.</mixed-citation><mixed-citation xml:lang="en">Dunlop B.W., DeFife J.A., Marx L., Garlow S.J., Nemeroff C.B., Lilienfeld S.O. The effects of sertraline on psychopathic traits. Int Clin Psychopharmacol. 2011;26(6):329–337. doi: 10.1097/YIC.0b013e32834b80df.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Benning S.D. Psychopathic Personality Inventory (PPI). Encyclopedia of Personality and Individual Differences, Springer International Publishing; 2016. pp. 1–4. doi: 10.1007/978-3-319-28099-8_1098-1.</mixed-citation><mixed-citation xml:lang="en">Benning S.D. Psychopathic Personality Inventory (PPI). Encyclopedia of Personality and Individual Differences, Springer International Publishing; 2016. pp. 1–4. doi: 10.1007/978-3-319-28099-8_1098-1.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Romero-Martínez Á., Murciano-Martí S., Moya- Albiol L. Is Sertraline a Good Pharmacological Strategy to Control Anger? Results of a Systematic Review. Behav Sci (Basel). 2019;9(5):57. doi: 10.3390/bs9050057.</mixed-citation><mixed-citation xml:lang="en">Romero-Martínez Á., Murciano-Martí S., Moya- Albiol L. Is Sertraline a Good Pharmacological Strategy to Control Anger? Results of a Systematic Review. Behav Sci (Basel). 2019;9(5):57. doi: 10.3390/bs9050057.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
